Skip to main content
. 2020 Sep;9(9):5614–5625. doi: 10.21037/tcr-20-2641

Figure 5.

Figure 5

The expression of UBE2M regulated chemotherapy resistance via the activation of β-catenin. (A) Protein levels of UBE2M in HCT116, HCT116 + siRNA, HCT116 + plasmid, SW480, SW480 + siRNA, and SW480 + plasmid cells were measured by western blot. (B) Quantitative representation of the band intensities. (C,D,E,F) HCT116, HCT116 + siRNA, HCT116 + plasmid, HCT116/5-FU, HCT116/5-FU + siRNA, HCT116/oxaliplatin, and HCT116/oxaliplatin + siRNA cells were treated with an increased dose of 5-FU and oxaliplatin for 72 h. Cell viability was determined according to CellTiter-Glo Luminescent Cell Viability Assay. (G) Protein levels of β-catenin in HCT116, HCT116 + siRNA, HCT116 + plasmid, SW480, SW480 + siRNA, and SW480 + plasmid cells were measured by western blot. (H) Quantitative representation of the band intensities. Statistical significance was determined by t test. ***, P<0.01. UBE2M, ubiquitin-conjugating enzyme E2 M; siRNA, small interfering ribonucleic acid.